Feedback on proposal to amend access criteria for type 2 diabetes medicines

Overview

We're seeking your feedback on a proposal for people living with Type 2 diabetes and at risk of cardio-renal complications. We are proposing to widen access to:

• empagliflozin (Jardiance)
• empagliflozin with metformin (Jardiamet)
• dulaglutide (Trulicity)
• liraglutide (Victoza)